Psilocybin-Induced Syncope in Clinical Trials: A Case Study

Introduction: A Rare Adverse Event

In a recent case report published on May 28, 2026, a rare but significant adverse event was documented during a psilocybin trial. The report, featured in OpenAlex, detailed an incident of neurocardiogenic syncope (NCS) in a healthy 35-year-old male participant. This event occurred approximately 60 minutes after the oral administration of 25 mg of psilocybin during an open-label study investigating psilocybin-evoked changes in brain function using transcranial magnetic stimulation and electroencephalography (TMS-EEG).

The participant experienced lightheadedness followed by a brief loss of consciousness and postural tone, with immediate blood pressure recorded at 93/51 mmHg, accompanied by tachycardia and diaphoresis. Supportive measures, including leg elevation and oral hydration, led to rapid stabilization, and no further cardiovascular abnormalities were noted.

Mechanisms and Context

The case underscores the complex interplay between psilocybin's pharmacological effects and physiological responses. Psilocybin, a serotonergic psychedelic, is known to influence the autonomic nervous system, potentially leading to cardiovascular changes. In this instance, the participant's upright seated posture, restrictive EEG equipment, and anticipatory anxiety surrounding TMS may have contributed to heightened autonomic arousal and susceptibility to NCS.

While transient hypertensive responses to psilocybin are well-documented, hypotensive events like NCS are rarely reported. This case highlights the need for comprehensive monitoring of both hypertensive and hypotensive events to better understand psilocybin's safety profile.

Implications for Research and Policy

As psilocybin approaches potential U.S. Food and Drug Administration (FDA) approval, the systematic characterization of adverse events becomes increasingly critical. This case report emphasizes the necessity for vigilant cardiovascular monitoring in psychedelic research, particularly during procedures that may amplify emotional arousal.

Fewer than one-quarter of contemporary psychedelic trials report systematic adverse event assessment. Transparent documentation of both hypertensive and hypotensive events is essential for defining psilocybin's safety profile as its clinical applications expand.

Risks and Unknowns

While this case provides valuable insights into the potential risks associated with psilocybin use, it also highlights the gaps in current research. The rarity of NCS in psychedelic trials suggests that such events may be underreported or overlooked. Further studies are needed to determine the prevalence and mechanisms of hypotensive events during psilocybin administration.

Moreover, the contextual factors contributing to this case, such as the participant's emotional state and the experimental setup, warrant further investigation to develop comprehensive safety protocols for future trials.

Looking Forward

This case report serves as a crucial reminder of the complexities involved in psychedelic research and the importance of meticulous safety measures. As psilocybin trials continue to expand, researchers must prioritize the systematic documentation of adverse events and implement robust monitoring protocols to ensure participant safety.

Ongoing and future trials should consider integrating enhanced cardiovascular monitoring and addressing contextual factors that may influence autonomic responses. These measures will be vital in establishing a comprehensive safety profile for psilocybin as it moves closer to clinical application.